TF-PROTACs Enable Targeted Degradation of Transcription Factors

Liu, Jing, Chen, He, Kaniskan, H. Ümit, Xie, Ling, Chen, Xian, Jin, Jian, Wei, Wenyi·2021·Journal of the American Chemical Society
DOI 10.1021/jacs.1c03852

Cited by (251)

Items 101–200 of 251

  1. MYC-Targeting PROTACs Lead to Bimodal Degradation and N-Terminal Truncation
    Shelton R. Boyd, Srinivas Chamakuri, Alexander J. Trostle, Hu Chen, Zhandong Liu, Antrix Jain, Jian Wang, Anna Malovannaya, Damian W. Young · 2025 · ACS Chemical Biology
  2. PROTAC: a revolutionary technology propelling small molecule drugs into the next golden age
    Jiale Cai, Chen Chen, Jiayue Wang, Xinmeng Zhang, Yuqiu Cui, Qunshan Zhu, Haibo Sun · 2025 · Frontiers in Oncology
  3. Key advances and application prospects of PROTAC technologies in the next 5 years
    Shuanglin Qin, Xiaohe Xiao · 2025 · Future Medicinal Chemistry
  4. Posttranslational modifications of E2F family members in the physiological state and in cancer: Roles, mechanisms and therapeutic targets
    Mingyang Sun, Yitong Ji, Guo‐Jun Zhang, Yang Li, Fengming Dong, Tianyi Wu · 2024 · Biomedicine & Pharmacotherapy
  5. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022
    T. N. Rekha, Dongyun Shin · 2023 · International Journal of Molecular Sciences
  6. Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
    Jing Liu, Yunhua Peng, Hiroyuki Inuzuka, Wenyi Wei · 2022 · Seminars in Cancer Biology
  7. Insights on the biological functions and diverse regulation of RNA-binding protein 39 and their implication in human diseases
    Morgane P. Eléouët, Chengpiao Lu, Yijia Zhou, Ping Xun Yang, Jingjing Ma, Guoqiang Xu · 2022 · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
  8. CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer
    Ning Zhang, Da Huang, Xiaohao Ruan, Ada Tsui‐Lin Ng, James Hok‐Leung Tsu, Guangliang Jiang, Jingyi Huang, Yongle Zhan, Rong Na · 2023 · Drug Resistance Updates
  9. Harnessing the Deubiquitinase USP1 for Targeted Protein Stabilization
    Chao Qian, Zhen Wang, Yan Xiong, Dingpeng Zhang, Yue Zhong, Hiroyuki Inuzuka, Yihang Qi, Ling Xie, Xian Chen, Wenyi Wei et al. · 2025 · Journal of the American Chemical Society
  10. Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
    Qiong Li, Li Zhou, Siyuan Qin, Zhao Huang, Bowen Li, Bowen Li, Mei Yang, Edouard Collins Nice, Huili Zhu, Canhua Huang · 2023 · European Journal of Medicinal Chemistry
  11. Photodegradation of carbonic anhydrase IX via a binding-enhanced ruthenium-based photosensitizer
    Hao Liang, Jie Wang, Zhengyin Pan, Zong‐Wan Mao, Cai-Ping Tan · 2022 · Chemical Communications
  12. Methylated Nucleotide-Based Proteolysis-Targeting Chimera Enables Targeted Degradation of Methyl-CpG-Binding Protein 2
    Zhen Wang, Jing Liu, Xing Qiu, Dingpeng Zhang, Hiroyuki Inuzuka, Li Chen, He Chen, Ling Xie, H. Ümit Kanıskan, Xian Chen et al. · 2023 · Journal of the American Chemical Society
  13. A heterobifunctional molecule recruits cereblon to an RNA scaffold and activates its PROTAC function
    Yan Xu, Dingqiang Fu, Yi Yuan, Yan Peng, Juan Dong, Feng Du, Xin Huang, Guangxun Li, Xiaohua Chen, Qiwei Wang et al. · 2022 · Cell Reports Physical Science
  14. Current Status of Oligonucleotide-Based Protein Degraders
    Po‐Chang Shih, Miyako Naganuma, Yosuke Demizu, Mikihiko Naito · 2023 · Pharmaceutics
  15. Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety
    Renshuai Zhang, Songbo Xie, Jie Ran, Te Li · 2024 · Journal of Cellular Physiology
  16. Targeted protein degradation technologies: Emerging mechanisms and nano-based innovations
    Mingge Hou, Runze Zhao, Shenghui Wang, Bing Jiang, Xiyun Yan · 2025 · Nano Research
  17. Human IGF2 Gene Epigenetic and Transcriptional Regulation: At the Core of Developmental Growth and Tumorigenic Behavior
    Pierluigi Scalia, Stephen John Williams, Yoko Fujita‐Yamaguchi · 2023 · Biomedicines
  18. Cell-Specific Degradation of Histone Deacetylase Using Warhead-Caged Proteolysis Targeting Chimeras
    Qi Jia, Yue Zhang, Feng Liu, Wanrong Dong, Lei Zhu, Fenglin Wang, Jian‐Hui Jiang · 2023 · Analytical Chemistry
  19. Recent advancements in targeted protein knockdown technologies—emerging paradigms for targeted therapy
    Mansi Joshi, Pranay Dey, Abhijit De · 2023 · Exploration of Targeted Anti-tumor Therapy
  20. From classic medicinal chemistry to state‐of‐the‐art interdisciplinary medicine: Recent advances in proteolysis‐targeting chimeras technology
    Xuyang Zhao, Yifan Chen, Huang Su, Liqin Zhang · 2023 · Interdisciplinary medicine
  21. Membrane‐Bounded Intracellular E3 Ubiquitin Ligase‐Targeting Chimeras (MembTACs) for Targeted Membrane Protein Degradation
    Mengwu Mo, Feiyu Wang, Huimin Zhang, Ying Zhang, Chaoyong James Yang, Jinbiao Shang, Zhi Zhu · 2025 · Angewandte Chemie International Edition
  22. Phenotypic Screening for Targeted Protein Degradation: Strategies, Challenges, and Emerging Opportunities
    Baoli Ding, Jiawen Hu, Binyan Shou, Jiang Li, Bo Yang, Ji Cao, Cheng‐Liang Zhu · 2025 · Journal of Medicinal Chemistry
  23. Ferroptosis-associated transcriptional factors in neurological diseases: molecular mechanisms and therapeutic prospects
    Tianchen Jiang, Waner Ma, Weibo Dong, Honghao Zhou, Xiaoyuan Mao · 2025 · Experimental & Molecular Medicine
  24. Targeted Protein Degradation: An Important Tool for Drug Discovery for “Undruggable” Tumor Transcription Factors
    Mengyuan Dai, Radhakrishnan Sridhar, Rui Li, Ruirong Tan, Kuo Yan, Gang Fan, Miao Liu · 2022 · Technology in Cancer Research & Treatment
  25. Targeting bacterial transcription factors for infection control: opportunities and challenges
    Ahmed Al-Tohamy, Anne Grove · 2023 · Transcription
  26. Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader
    Md Kabir, Lihuai Qin, Kaixiu Luo, Yan Xiong, Rebecca A. Sidi, Kwang‐Su Park, Jian Jun Jin · 2024 · Journal of Medicinal Chemistry
  27. ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance
    Cheol‐Jung Lee, Hee-Jung Lee, Seoree Kim, Soo-Bin Nam, Ga-Eun Lee, Kyeong Eun Yang, Guk Jin Lee, Sang Hoon Chun, Han Chang Kang, Joo Young Lee et al. · 2024 · Cell Death and Disease
  28. ZIF-90-loaded DNAzyme-responsive PROTAC for the self-powered degradation of NF-κB
    Min Hou, Liang Sun, Tianyu Ren, Mingda Li, Chaosu Hu, Rong Liu, Shuang Gu, Mingyan Jiang, Jian‐Hui Jiang, Jianjun He · 2024 · Science China Chemistry
  29. An instructive attempt on developing aptamer-constructed PROTAC for breast cancer treatment
    Yuzhu Zhang, Dazhao Mi, Yihua Chen · 2022 · Molecular Therapy — Nucleic Acids
  30. Structural Optimization of Decoy Oligonucleotide-Based PROTAC That Degrades the Estrogen Receptor
    Miyako Naganuma, Nobumichi Ohoka, Genichiro Tsuji, Takao Inoué, Mikihiko Naito, Yosuke Demizu · 2023 · Bioconjugate Chemistry
  31. Recent Advances in PROTAC Technology Toward New Therapeutic Modalities
    Hidetomo Yokoo, Miyako Naganuma, Makoto Oba, Yosuke Demizu · 2022 · Chemistry & Biodiversity
  32. C2H2 Zinc Finger Transcription Factors Associated with Hemoglobinopathies
    Xing Zhang, Fangfang Xia, Xiaotian Zhang, Robert Blumenthal, Xiaodong Cheng · 2023 · Journal of Molecular Biology
  33. Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers
    Li Liu, Lihong Shi, Zhaodi Wang, Jun Zeng, Yue Wang, Hongtao Xiao, Yongxia Zhu · 2022 · Frontiers in Endocrinology
  34. ATF family members as therapeutic targets in cancer: From mechanisms to pharmacological interventions
    Xueyao Zhang, Zhijia Li, Xiaochun Zhang, Ziyue Yuan, Lan Zhang, Peng Miao · 2024 · Pharmacological Research
  35. Systematic evolution of functional oligonucleotides for targeted protein degradation
    Huang Su, Yifan Chen, Xuyang Zhao, Ziang Lu, Tongxuan Wei, Qinguo Liu, Xiyang Liu, Qinhao Zhang, Siqi Bian, Qibing Qiu et al. · 2025 · Chem
  36. Circular mRNA encoded PROTAC (RiboPROTAC) as a new platform for the degradation of intracellular therapeutic targets
    Jiali Yang, Jiaojiao Sun, Jiafeng Zhu, Yaran Du, Yiling Tan, Lixiang Wei, Yang Zhao, Qiangbo Hou, Yan Zhang, Zhenhua Sun et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  37. Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemia
    Xudong Li, Wei Li, Yanli Zhang, Linping Xu, Yongping Song · 2023 · Genes & Diseases
  38. Hydrophobic CPP/HDO conjugates: a new frontier in oligonucleotide-warheaded PROTAC delivery
    Miyako Naganuma, Nobumichi Ohoka, Motoharu Hirano, Daishi Watanabe, Genichiro Tsuji, Takao Inoué, Yosuke Demizu · 2024 · RSC Medicinal Chemistry
  39. PROTAC as a novel anti-cancer strategy by targeting aging-related signaling
    Yunhua Peng, Donghua Liu, Daoyuan Huang, Hiroyuki Inuzuka, Jing Liu · 2024 · Seminars in Cancer Biology
  40. In Vivo Self‐Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy
    Shaowen Xie, Jingjie Zhu, Yihan Peng, Fangyi Zhan, Feiyan Zhan, Chen He, Dazhi Feng, Jia Qing Xie, Jingyu Liu, Huajian Zhu et al. · 2024 · Angewandte Chemie
  41. Targeting the cell-cycle machinery for cancer therapy
    Yunhua Peng, Jiejing Liu, Hiroyuki Inuzuka, Jing Liu, Wenyi Wei · 2025 · Trends in Cell Biology
  42. mRNA PROTACs: engineering PROTACs for high‐efficiency targeted protein degradation
    Xiaoqi Xue, Chen Zhang, Xiaolin Li, Junqiao Wang, Haowei Zhang, Ying Feng, Naihan Xu, Hongyan Li, Chunyan Tan, Yuyang Jiang et al. · 2024 · MedComm
  43. Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs
    Rui Yao, Tianli Luo, Ming Wang · 2023 · ChemBioChem
  44. RNA G-quadruplex structure-based PROTACs for targeted DHX36 protein degradation and gene activity modulation in mammalian cells
    Kun Zhang, Qichang Nie, Maolin Li, Xiaona Chen, Liting Zhong, Tianle Dai, Xiaofan Guo, Haizhou Zhao, Terrence Chi‐Kong Lau, Huating Wang et al. · 2025 · Nucleic Acids Research
  45. An updated review on the role of small molecules in mediating protein degradation
    Zumei Wu, Yulong Li, Jinyun Dong, Jiang‐Jiang Qin · 2025 · European Journal of Medicinal Chemistry
  46. Harnessing the Power of Natural Products for Targeted Protein Degradation
    Bo Zhu, Zheng Wu, Yiwen Shou, Kaili Zhao, Qinpei Lu, Jiang‐Jiang Qin, Hongwei Guo · 2025 · Medicinal Research Reviews
  47. Shaping Orthodontics of the Future: Concepts and Implications from a Cellular and Molecular Perspective
    Thorsten Steinberg, Britta A. Jung, Ayman Husari, Shuoqiu Bai, Pascal Tomakidi · 2025 · International Journal of Molecular Sciences
  48. Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation
    Mohamed S. Nafie, Mohamed Khaled Diab, Asmaa S. A. Yassen, Amany M. Elshamy, Mohamed R. El Tohamy, Haytham O. Tawfik, Sherif Ashraf Fahmy · 2025 · Drug Development Research
  49. NF-κB fingerprinting reveals heterogeneous NF-κB composition in diffuse large B-cell lymphoma
    Eleanor S. Jayawant, Arran Pack, Heather Clark, Emma Kennedy, Ankur Ghodke, John R Jones, Chris J. Pepper, Andrea G. S. Pepper, Simon A. Mitchell · 2023 · Frontiers in Oncology
  50. PROTACs coupled with oligonucleotides to tackle the undruggable
    Guangshuai Zhang, Si Yan, Yan Liu, Ziwei Du, Qin Min, Shuanglin Qin · 2025 · Bioanalysis
  51. (GGAA)3-Based TF-PROTACs Enable Targeted Degradation of ETV6 to Inhibit Ewing Sarcoma Growth
    Zhichuan Zhu, He Chen, Xing Qiu, H. Ümit Kanıskan, Ling Xie, Xian Chen, Jian Jun Jin, Pengda Liu · 2025 · Journal of the American Chemical Society
  52. Ubiquitination of transcription factors in cancer: unveiling therapeutic potential
    Dongha Kim, Hye Jin Nam, Sung Hee Baek · 2025 · Molecular Oncology
  53. Synthetic approaches to constructing proteolysis targeting chimeras (PROTACs)
    Olga Bakulina, Alexander Sapegin, Alexander Siyasatovich Bunev, Mikhail Krasavin · 2022 · Mendeleev Communications
  54. PROTAC technology for prostate cancer treatment
    Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, Wenyi Wei · 2025 · Acta Materia Medica
  55. PROTAC Degraders
    Alessio Ciulli, Oliver Hsia · 2022 · Wiley eBooks
  56. Design and synthesis of nucleic acid nano-environment interactome-targeting small molecule PROTACs and their anticancer activity
    Sadiya Tanga, Arkadeep Karmakar, Arpita Hota, Paramita Banerjee, Basudeb Maji · 2024 · Nanoscale
  57. Recent breakthroughs in innovative elements, multidimensional enhancements, derived technologies, and novel applications of PROTACs
    Si-Han Zhang, Na Zeng, Jin‐Zhou Xu, Chen‐Qian Liu, Mengyao Xu, Jian‐Xuan Sun, Ye An, Xing‐Yu Zhong, Lin-Tao Miao, Shaogang Wang et al. · 2024 · Biomedicine & Pharmacotherapy
  58. Alternative Strategies of Reducing MYC Expression for the Treatment of Cancers
    Huijuan Chen, Song Jingfeng, Yihang Wang, Zhijin Peng, Hongyu Zeng, Hu Zhou, Wenbin Shang, Yihua Chen · 2026 · Journal of Medicinal Chemistry
  59. A model-informed method to retrieve intrinsic from apparent cooperativity and project cellular target occupancy for ternary complex-forming compounds
    Richard R. Stein, Marianne Fouché, Jeffrey D. Kearns, H.‐J. ROTH · 2023 · RSC Chemical Biology
  60. Selective Proteolysis of Activated Transcriptional Factor by NIR‐Responsive Palindromic DNA Thalidomide Conjugate Inhibits the Canonical Smad Pathway
    Min Hou, Rui Guo, Tianyu Ren, Tao Wang, Jian‐Hui Jiang, Jianjun He · 2023 · Small
  61. Major Advances in Emerging Degrader Technologies
    Hang Luo, Li Wu, Yujian He, Chong Qin, Xinjing Tang · 2022 · Frontiers in Cell and Developmental Biology
  62. Oncogenic FLT3 internal tandem duplication activates E2F1 to regulate purine metabolism in acute myeloid leukaemia
    Ziyao Ou, Ke Wang, Wen-wen Shen, Ge Deng, Yayun Xu, Long-Fei Wang, Zhuoyan Zai, Yian Ling, Tao Zhang, Xiaoqing Peng et al. · 2023 · Biochemical Pharmacology
  63. Selection of DNA-encoded Chemical Libraries for Compounds that can Induce Protein Ubiquitination
    Cen Huang, Xing‐Yuan Liu, Xinyuan Wu, Ling Hua Meng, Xiaojie Lu, Xiaoyu Li · 2024 · ChemRxiv
  64. Advances in DNA-based proteolysis-targeting chimeras technology: Novel strategies for targeting previously undruggable proteins in cancer therapy
    Min Hou, Mingda Li, Yulin Li, Xiaohua Wu, Die Long, Di Sun, Jincheng Zeng · 2025 · Bioorganic & Medicinal Chemistry
  65. TCF/LEF-mediated transcriptional regulation in the canonical Wnt pathway
    Chika Takano, Yusuke Higuchi · 2025 · Current Molecular Pharmacology
  66. An overview of recent advancements in targeted cancer therapies and their potential clinical impact
    Shujauddin Ahmed, Akash P. Sakla, Kousar Jahan, Naziya Neshat, Mymoona Akhter, Shams Aaghaz, Ahmed Kamal · 2025 · RSC Medicinal Chemistry
  67. Proteasomal control of transcription factors: mechanisms, regulation and dysregulation
    Fia B. Larsen, Birthe Brandt Kragelund, Kresten Lindorff‐Larsen, Pétur O. Heidarsson, Rasmus Hartmann‐Petersen · 2026 · Cellular and Molecular Life Sciences
  68. Chemical immunology: Recent advances in tool development and applications
    Yujie Shi, Eleanor E. Bashian, Yingqin Hou, Peng Wu · 2024 · Cell chemical biology
  69. Identification and characterization of ternary complexes consisting of FKBP12, MAPRE1 and macrocyclic molecular glues
    Michael Salcius, Antonin V. Tutter, Marianne Fouché, Halil Koc, Dan King, Anxhela Dhembi, Andrei A. Golosov, Wolfgang Jahnke, Chrystèle Henry, Dayana Argoti et al. · 2025 · RSC Chemical Biology
  70. Utilizing Alkyne‐Nitrone Cycloaddition for the Convenient Multi‐Component Assembly of Protein Degraders and Biological Probes
    Shiou‐Ting Lin, Chien‐Hua Wang, Ailin Chen, Tsung‐Shing Andrew Wang · 2024 · Chemistry - A European Journal
  71. Injectable PROTAC-loaded hydrogel remodels the tumor microenvironment to potentiate radio-immunotherapy
    Weihe Zhao, Xiangdong Xu, Shu An, Juehui Wu, Haiyang Wang, Jinmei Luo, Youyuan Yuan, Laisheng Li · 2025 · Journal of Controlled Release
  72. Degradation of G‐Quadruplex‐Binding Proteins by G4L‐PROTAC via Quaternary Complex Formation
    Rena Nohara, Yuma Tanaya, Mohammad Jafar Sheikhi, Pratiksha Chaudhary, Grinsun Sharma, Hanbin Mao, Kazuo Nagasawa, Masayuki Tera · 2025 · Angewandte Chemie International Edition
  73. Evolution of proteolysis-targeting chimeras (PROTAC) technology to overcome challenges of antimicrobial resistance
    Dhanashree N. Sarwan, Pramod Bhujangrao Khedekar, Ritesh P. Bhole, Rupesh V. Chikhale · 2025 · npj Antimicrobials and Resistance
  74. Engineering Polymeric Nano-PROTAC for Targeted Protein Degradation and Cancer Therapy
    Madiha Saeed, Zainab Amina, Zhiai Xu, Haijun Yu · 2026 · Polymer science & technology.
  75. To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives
    Diana Castagna, Benoit Gourdet, Roland Hjerpe, Philip MacFaul, Andrew Novak, Guillaume Révol, Étienne Rochette, Allan Michael Jordan · 2024 · Progress in medicinal chemistry
  76. Multivalent DNA lysosome-targeting chimaera for targeted protein degradation and inhibition of c-Met signaling pathways
    Xinhuan Chen, Mengmeng Ji, Xue Bai, Tianlu Zhang, Xiao Li, Yuanrui Wang, Wei Li, Huazhi Geng, Xin Li, Jing Lu et al. · 2025 · Chemical Engineering Journal
  77. Unconventional PROTACs for Targeted Protein Degradation in Cancer Therapy
    Xu Zhang, Zhangzhi Song, Xinyu Zhang, Jianhua Zou, Guocan Yu, Xiaoyuan Shawn Chen, Sheng Wang · 2025 · Angewandte Chemie
  78. Current advances in the proteolysis-targeting chimeras (PROTACs) delivery systems
    Zhanzhan Feng, Shuyan Zhou, Xiao Li, Guoquan Wan, Kaiyan Xu, Zhiyong Qian · 2025 · Chinese Chemical Letters
  79. Targeted Degradation of Lin28B Using Pre-let-7-PROTACs for Hepatocellular Carcinoma Therapy
    Jianfei Xu, Xingxing Liang, Zhaopeng Yan, Yuejie Zhu, Jing Wang, Qian Wang, Zhenjun Yang, Xinjing Tang · 2026 · Journal of Medicinal Chemistry
  80. PROTACs in targeted protein degradation: Advances in development and AI-enhanced drug discovery
    Mao Du, Tao Liu, Wenyu Wang, Shuai Fan, Mei Tian, Qing Du, Zhidong Wang, Xiaodong Li, Xiaoyu Liu, Qin Xia et al. · 2026 · European Journal of Medicinal Chemistry Reports
  81. Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications
    Nikola Knoll, Nouri Neamati, Aykut Üren · 2026 · ACS Pharmacology & Translational Science
  82. From undruggable to degradable: Strategic expansion of targeted protein degradation in cancer therapy
    Jiyoon Sung, Yuna Seo, Jae-Young Lee · 2026 · Molecular Therapy
  83. G‐Quadruplex RNA Based PROTAC Enables Targeted Degradation of RNA Binding Protein FMRP for Tumor Immunotherapy
    Ruixi Peng, Qian Huang, Li Wang, Gongxi Qiao, Xiangrong Huang, Jian‐Hui Jiang, Xia Chu · 2024 · Angewandte Chemie
  84. Experimental Conditions to Retrieve Intrinsic Cooperativity α Directly from Single Binding Assay Data Exemplified by the Ternary Complex Formation of FKBP12, MAPRE1 and Macrocyclic Molecular Glues
    Jan Schnatwinkel, Richard R. Stein, Michael Salcius, Julian L. Wong, Shuyu Chen, Marianne Fouché, H.‐J. ROTH · 2025 · International Journal of Molecular Sciences
  85. On-demand modular assembly for expedited PROTAC development
    Ayan Mukherjee, Vilas D. Kadam, Qi Miao, Wanheng Zhang, Kevin R. MacKenzie, Zhi Tan, Mingxing Teng · 2024 · Expert Opinion on Drug Discovery
  86. Discovery of 2-Pyrazolylpyrimidinone Derivatives as New SPOP Inhibitors for Renal Cell Carcinoma Therapy
    Qiong Zhang, Yangguo Zhou, Jinglong Zhao, Lvbin Hu, Zhiwei Zhu, Huifang Wang, Yuhui Jin, Qidong You, Zhengyu Jiang, Xiaoke Guo · 2025 · Journal of Medicinal Chemistry
  87. Differential Impact of Recruited and Resident Macrophages on Hypoxia-Induced Pulmonary Hypertension
    Shumin Guo, Ting Pan, Xiaojie Yan, Cheng Yuanyuan, Ronglu Du, Qian Liu, Yongle Huang, Yujuan Zhuo, Yan Zhao, Danyang Tian et al. · 2025 · Circulation Research
  88. Fulfilling multiple roles in PROTAC design: The emerging potential of oligonucleotides
    Daniel Alencar Rodrigues, Gustavo Salgado Pires, Urbi Roy, Eric Conway, Pedro de Sena Murteira Pinheiro · 2026 · European Journal of Medicinal Chemistry
  89. Bridged PROTAC, DNA-based PROTAC and hydrophobic tag technologies for targeted protein degradation
    Pengcheng Gao, Yue Zhong, Kaixiu Luo, Jian Jun Jin · 2026 · Advanced Drug Delivery Reviews
  90. Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy
    Rangzi Yi, Zijian Zhang, Yang Yang, Haichuan Zhu · 2026 · Cancer Innovation
  91. Multifaceted targeted protein degradation systems for different cellular compartments
    Cornelia E. Zorca, Armaan Fallahi, Sophie Luo, Mohamed A. Eldeeb · 2022 · BioEssays
  92. Proteolysis-Targeting Chimeras: A Kaleidoscope of Targeted Protein Degradation
    Yi Mou, Shuai Wen, Xinxing Gao, Zhengyu Jiang · 2021 · Future Medicinal Chemistry
  93. Small Molecules Targeting HSF1 Pathway: Chemical Strategies and Therapeutic Potential
    Caiyiren Wen, Yiqi Geng, Jiayue Pei, Qidong You, Lei Wang · 2025 · Journal of Medicinal Chemistry
  94. Near‐Infrared Light‐Activated Transcription Factor‐Targeted Proteolysis‐Targeting Chimeras Nanomachine for Targeted Degradation of Transcription Factors
    Bei Zhou, Junqing Yang, Bin Zhang, Weishan Wang, Jinbo Li, Yan Zhang · 2025 · ChemBioChem
  95. “Leucine zipper proteins as emerging therapeutic regulators: structural dynamics, disease associations, and novel targeting strategies”
    Anjali Kumari, Adiba Mussarrat, Manodeep Chakraborty, Ananya Bhattacharjee, Ravi Kumar Rajan · 2025 · Cell Cycle
  96. Chemistry-Driven Integrated Innovation: Unleashing the Potential of PROTAC Technology
    Hui Xu, Kai Tang, Yuning Song, Luis Menéndez‐Arias, Peng Zhan · 2025 · Pharmaceutical Fronts
  97. Advances in novel modification strategies for enhancing the tumor tissue specificity of PROTACs
    Liuzhi Hu, Shuang Wu, Wentao Wang, Hongbo He, Jinxin Che, Mingfei Wu, Xiaowu Dong · 2025 · European Journal of Medicinal Chemistry
  98. BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1/2-Cyclin D1/CDK4/6 axis
    Ting Wu, Shuang Qi, Chenliang Shi, Chao Wu, Qingwang Liu, Chen Hu, Jie Hu, Aoli Wang, Jing Liu, Ziyue Qi et al. · 2026 · Signal Transduction and Targeted Therapy
  99. Discovery of New OTUB1 Covalent Ligands via Structure–Activity Relationship Studies for Targeted Protein Stabilization
    Xiangyang Song, Qiong Wu, Li Chen, Hiroyuki Inuzuka, Yue Zhong, Yihang Qi, Yindan Lin, Md Kabir, Yan Xiong, Wenyi Wei et al. · 2026 · Journal of Medicinal Chemistry
  100. Targeted O-GlcNAcylation enables functional rewiring of c-Myc
    Tongyang Xu, Zhihao Guo, Khadija Shahed Khan, Yunpeng Huang, Bowen Ma, Shuhui Ji, Jialin Liu, Dean W. Felsher, B. K.W. NG · 2026 · Cell chemical biology